E. Coli endotoxin
PreclinicalSmall molecule
E. Coli endotoxin is one of 15 small molecule programs targeting Hyperbilirubinemia. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
11 competitors in Hyperbilirubinemia
#DrugCompanyPhaseTrials
1Verazinc
FFakultas Kedokteran Universitas Indonesia
Phase 2
Medrol
PfizerPreclinical
Tricor
JJagotec
Preclinical
Legalon
BBukwang Pharmaceutical
Preclinical
Reyataz
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Deltavit
HHyundai Pharmaceutical Co., LTD.
Preclinical
Glutathione
UUniversity of Chicago
Preclinical
E. Coli endotoxin
RRadboud University Medical Center
Preclinical
Bifidobacterium Animalis Subsp. Lactis
UUniversity of Sao Paulo
Preclinical
Ademetionine 1,4-Butanedisulfonate
CChina National Center for Cardiovascular Diseases
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for E. Coli endotoxin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details